Facet Biotech

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Facet Biotech sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Facet Biotech: 13 sponsored US clinical trials, none currently recruiting.

Facet Biotech sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Graft Vs Host Disease, with 1 trials.

Top-decile sponsor footprint

Facet Biotech ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 32/100

10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

TERMINATED Phase 2

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
COMPLETED Phase 1

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

NCT00425347
TERMINATED Phase 2

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
TERMINATED Phase 2

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00279422
COMPLETED Phase 2

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

NCT00267722
COMPLETED Phase 2

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

NCT00267709
COMPLETED Phase 1

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

NCT00267306
COMPLETED Phase 2

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047
COMPLETED Phase 1

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292
COMPLETED Phase 2

Research Study in Patients With Severe Ulcerative Colitis

NCT00032305
COMPLETED Phase 2

A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

NCT00072943
COMPLETED Phase 2

Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288
COMPLETED Phase 2

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 10

Therapeutic Areas

Graft Vs Host Disease 1

How the Facet Biotech early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).

Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Graft Vs Host Disease (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Facet Biotech: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Facet Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share Facet BiotechAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Facet Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Facet Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Facet Biotech page

13 registered trials is a research-attention snapshot, not an endorsement of Facet Biotech or any single study.

  • None of Facet Biotech's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Graft Vs Host Disease is the condition Facet Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Graft Vs Host Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Facet Biotech pipeline card: 13 registered trials from official public datasets.Report a data error.